CA3013047A1 - Use of histone deacetylase inhibitors for enhancing immunotherapies - Google Patents
Use of histone deacetylase inhibitors for enhancing immunotherapies Download PDFInfo
- Publication number
- CA3013047A1 CA3013047A1 CA3013047A CA3013047A CA3013047A1 CA 3013047 A1 CA3013047 A1 CA 3013047A1 CA 3013047 A CA3013047 A CA 3013047A CA 3013047 A CA3013047 A CA 3013047A CA 3013047 A1 CA3013047 A1 CA 3013047A1
- Authority
- CA
- Canada
- Prior art keywords
- entinostat
- phenyl
- methyl
- inhibitor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims description 23
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims description 18
- 238000009169 immunotherapy Methods 0.000 title abstract description 31
- 230000002708 enhancing effect Effects 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 25
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 21
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 21
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 19
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 19
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 16
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical group NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 103
- 229950005837 entinostat Drugs 0.000 claims description 100
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 17
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 17
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 17
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 10
- 229960003301 nivolumab Drugs 0.000 claims description 9
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 7
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 6
- -1 4-pyridin-3-ylpyrimidin-2-yl Chemical group 0.000 claims description 6
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims description 6
- 229960000604 valproic acid Drugs 0.000 claims description 6
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 claims description 5
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 5
- 229960003094 belinostat Drugs 0.000 claims description 4
- 229960005184 panobinostat Drugs 0.000 claims description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims description 3
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229950005259 dacinostat Drugs 0.000 claims description 3
- 229950007812 mocetinostat Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 108010060597 trapoxin A Proteins 0.000 claims description 3
- 229960000237 vorinostat Drugs 0.000 claims description 3
- XDIZHPIJCOYHPV-UHFFFAOYSA-N n'-hydroxy-n'-phenyloctanediamide Chemical compound NC(=O)CCCCCCC(=O)N(O)C1=CC=CC=C1 XDIZHPIJCOYHPV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims 2
- JKVNVKOVLBVYHQ-UHFFFAOYSA-N n-[[4-[3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide Chemical compound C1=CC(C=CC(=O)NO)=CC=C1CNC(=O)C1=CC=C(N2CCCC2)C=C1 JKVNVKOVLBVYHQ-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 68
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 62
- 238000011282 treatment Methods 0.000 description 54
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 47
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 23
- 108090000695 Cytokines Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 18
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 15
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 11
- 102000019034 Chemokines Human genes 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000011284 combination treatment Methods 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 102100021723 Arginase-1 Human genes 0.000 description 7
- 101710129000 Arginase-1 Proteins 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 6
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002975 chemoattractant Substances 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000037451 immune surveillance Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001024 immunotherapeutic effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011870 unpaired t-test Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000005667 attractant Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 230000006028 immune-suppresssive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 101150075117 Ccl12 gene Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000002100 tumorsuppressive effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 101100514575 Arabidopsis thaliana MT1A gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102000003826 Chemokine CCL17 Human genes 0.000 description 1
- 108010082169 Chemokine CCL17 Proteins 0.000 description 1
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 102100031506 Complement C5 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102100037765 Periostin Human genes 0.000 description 1
- 101710199268 Periostin Proteins 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004518 activated T cell apoptosis Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002482 anti-endothelial effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006867 granzyme B production Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- JFRJCQJVFMHZOO-QZHHGCDDSA-N n-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide Chemical compound C1=CC(CC(=O)NCCN)=CC=C1NC(=O)CC(C=C1)=CC=C1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JFRJCQJVFMHZOO-QZHHGCDDSA-N 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288121P | 2016-01-28 | 2016-01-28 | |
| US62/288,121 | 2016-01-28 | ||
| PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3013047A1 true CA3013047A1 (en) | 2017-08-03 |
Family
ID=58010402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3013047A Abandoned CA3013047A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10813919B2 (enExample) |
| EP (1) | EP3407913A1 (enExample) |
| JP (1) | JP2019503386A (enExample) |
| KR (1) | KR20180104122A (enExample) |
| CN (1) | CN108883179A (enExample) |
| AU (1) | AU2017211383A1 (enExample) |
| BR (1) | BR112018015291A2 (enExample) |
| CA (1) | CA3013047A1 (enExample) |
| IL (1) | IL260765A (enExample) |
| MX (1) | MX2018009247A (enExample) |
| RU (1) | RU2018130831A (enExample) |
| WO (1) | WO2017132536A1 (enExample) |
| ZA (1) | ZA201805066B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR102603681B1 (ko) | 2016-12-07 | 2023-11-17 | 아게누스 인코포레이티드 | 항체 및 이의 사용방법 |
| JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
| EP4385024A4 (en) | 2021-08-11 | 2025-06-25 | Oncohost Ltd | PREDICTING PATIENT RESPONSE |
| WO2024231293A1 (en) * | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| WO2024238811A2 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same |
| WO2025155922A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Indiana University | Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600281A (en) | 2006-12-27 | 2013-03-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| CN107614011A (zh) | 2015-03-20 | 2018-01-19 | 欣达克斯制药公司 | Hdac抑制剂和抗pd‑1抗体联合用于癌症的治疗 |
| WO2017035453A1 (en) * | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| KR102631377B1 (ko) | 2015-09-02 | 2024-01-29 | 신닥스 파마슈티컬스, 인크. | 조합 요법을 위한 환자의 선별 |
-
2017
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en not_active Ceased
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko not_active Withdrawn
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018130831A (ru) | 2020-03-02 |
| MX2018009247A (es) | 2019-03-11 |
| ZA201805066B (en) | 2019-05-29 |
| EP3407913A1 (en) | 2018-12-05 |
| CN108883179A (zh) | 2018-11-23 |
| US20190030011A1 (en) | 2019-01-31 |
| US10813919B2 (en) | 2020-10-27 |
| JP2019503386A (ja) | 2019-02-07 |
| KR20180104122A (ko) | 2018-09-19 |
| WO2017132536A1 (en) | 2017-08-03 |
| BR112018015291A2 (pt) | 2018-12-18 |
| IL260765A (en) | 2018-10-31 |
| RU2018130831A3 (enExample) | 2020-04-23 |
| AU2017211383A1 (en) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10813919B2 (en) | Use of histone deacetylase inhibitors for enhancing immunotherapies | |
| Shen et al. | Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models | |
| Iclozan et al. | Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | |
| Mokarizadeh et al. | Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling | |
| Wood et al. | Regulatory immune cells in transplantation | |
| Beres et al. | Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease | |
| Devasia et al. | Bispecific antibodies in the treatment of multiple myeloma | |
| Ridnour et al. | NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay | |
| Panek et al. | Local application of autologous platelet-rich fibrin patch (PRF-P) suppresses regulatory T cell recruitment in a murine glioma model | |
| JP2018522045A (ja) | Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 | |
| CN114286681A (zh) | Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂 | |
| Wachowska et al. | Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy | |
| Wang et al. | LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice | |
| Shi et al. | Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer | |
| JP2023027220A (ja) | Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ | |
| CA2819829A1 (en) | Compositions and methods for treating foxp3+ treg related diseases | |
| KR101968184B1 (ko) | 저산소 조건을 이용한 면역세포의 증식 배양 방법 | |
| US20230172984A1 (en) | CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS | |
| Tanwar et al. | Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE | |
| ES2789574T3 (es) | Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor | |
| Sun et al. | MCC950 attenuates plasma cell mastitis in an MDSC-dependent manner | |
| Liu et al. | Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity | |
| CN104138391B (zh) | 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用 | |
| KR102538055B1 (ko) | 사이토카인 폭풍 조절제 스크리닝 방법 | |
| Foureau et al. | Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220727 |
|
| FZDE | Discontinued |
Effective date: 20220727 |